Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar

<h3>Introduction</h3><p dir="ltr">Guillain-Barré syndrome (GBS) is an immune-mediated peripheral neuropathy that was reported following meningococcus, polio, influenza and rabies vaccines. However, an association with the COVID-19 vaccine is yet to be established. </p&...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Almurtada Razok (12204854) (author)
مؤلفون آخرون: Abdullah Shams (14136646) (author), Ahmed Almeer (21250805) (author), Muhammad Zahid (4510696) (author)
منشور في: 2021
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513549201571840
author Almurtada Razok (12204854)
author2 Abdullah Shams (14136646)
Ahmed Almeer (21250805)
Muhammad Zahid (4510696)
author2_role author
author
author
author_facet Almurtada Razok (12204854)
Abdullah Shams (14136646)
Ahmed Almeer (21250805)
Muhammad Zahid (4510696)
author_role author
dc.creator.none.fl_str_mv Almurtada Razok (12204854)
Abdullah Shams (14136646)
Ahmed Almeer (21250805)
Muhammad Zahid (4510696)
dc.date.none.fl_str_mv 2021-07-03T03:00:00Z
dc.identifier.none.fl_str_mv 10.1016/j.amsu.2021.102540
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Post-COVID-19_vaccine_Guillain-Barr_syndrome_first_reported_case_from_Qatar/28937660
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Immunology
Neurosciences
COVID-19 vaccine
Guillain-Barré syndrome
Molecular mimicry
Qatar
dc.title.none.fl_str_mv Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Introduction</h3><p dir="ltr">Guillain-Barré syndrome (GBS) is an immune-mediated peripheral neuropathy that was reported following meningococcus, polio, influenza and rabies vaccines. However, an association with the COVID-19 vaccine is yet to be established. </p><h3>Presentation of case</h3><p dir="ltr">We present the case of an elderly gentleman with no history of SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with GBS 20 days after the second dose of COVID-19 vaccination. The diagnosis was established based on physical examination, magnetic resonance imaging (MRI) of the spine, cerebrospinal fluid (CSF) analysis and electromyography (EMG). </p><h3>Discussion</h3><p dir="ltr">Due to the occurrence of GBS after certain types of infections, molecular mimicry has become widely acceptable as the underlying pathophysiology. The reported cases of GBS following vaccination further supported this theory, however proving a causal relationship between vaccines and GBS on the molecular level remains a challenge. </p><h3>Conclusions</h3><p dir="ltr">To the best of our knowledge this is the first reported case in the state of Qatar. It is important to mention that more research is needed to establish an association between COVID-19 vaccine and GBS. In our opinion, the benefits of COIVID-19 vaccine largely outweigh its risks.</p><h2>Other Information</h2><p dir="ltr">Published in: Annals of Medicine & Surgery<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.amsu.2021.102540" target="_blank">https://dx.doi.org/10.1016/j.amsu.2021.102540</a></p>
eu_rights_str_mv openAccess
id Manara2_4d1fb05e2cf6a7a7c52162e9835e4693
identifier_str_mv 10.1016/j.amsu.2021.102540
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/28937660
publishDate 2021
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from QatarAlmurtada Razok (12204854)Abdullah Shams (14136646)Ahmed Almeer (21250805)Muhammad Zahid (4510696)Biomedical and clinical sciencesImmunologyNeurosciencesCOVID-19 vaccineGuillain-Barré syndromeMolecular mimicryQatar<h3>Introduction</h3><p dir="ltr">Guillain-Barré syndrome (GBS) is an immune-mediated peripheral neuropathy that was reported following meningococcus, polio, influenza and rabies vaccines. However, an association with the COVID-19 vaccine is yet to be established. </p><h3>Presentation of case</h3><p dir="ltr">We present the case of an elderly gentleman with no history of SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with GBS 20 days after the second dose of COVID-19 vaccination. The diagnosis was established based on physical examination, magnetic resonance imaging (MRI) of the spine, cerebrospinal fluid (CSF) analysis and electromyography (EMG). </p><h3>Discussion</h3><p dir="ltr">Due to the occurrence of GBS after certain types of infections, molecular mimicry has become widely acceptable as the underlying pathophysiology. The reported cases of GBS following vaccination further supported this theory, however proving a causal relationship between vaccines and GBS on the molecular level remains a challenge. </p><h3>Conclusions</h3><p dir="ltr">To the best of our knowledge this is the first reported case in the state of Qatar. It is important to mention that more research is needed to establish an association between COVID-19 vaccine and GBS. In our opinion, the benefits of COIVID-19 vaccine largely outweigh its risks.</p><h2>Other Information</h2><p dir="ltr">Published in: Annals of Medicine & Surgery<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.amsu.2021.102540" target="_blank">https://dx.doi.org/10.1016/j.amsu.2021.102540</a></p>2021-07-03T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.amsu.2021.102540https://figshare.com/articles/journal_contribution/Post-COVID-19_vaccine_Guillain-Barr_syndrome_first_reported_case_from_Qatar/28937660CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/289376602021-07-03T03:00:00Z
spellingShingle Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
Almurtada Razok (12204854)
Biomedical and clinical sciences
Immunology
Neurosciences
COVID-19 vaccine
Guillain-Barré syndrome
Molecular mimicry
Qatar
status_str publishedVersion
title Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
title_full Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
title_fullStr Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
title_full_unstemmed Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
title_short Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
title_sort Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
topic Biomedical and clinical sciences
Immunology
Neurosciences
COVID-19 vaccine
Guillain-Barré syndrome
Molecular mimicry
Qatar